Health Canada endorsed important safety information on Paclitaxel for injection, 300mg/50mL

Hospira Healthcare Corporation, in consultation with Health Canada, would like to inform you that complaints were received from customers outside of Canada of visible vial defects for multiple products. The vial defects may manifest as particles embedded in the glass vial, as rust-like marks on the vial or as particles in the solution. Three lots of Paclitaxel distributed in Canada were manufactured using the same affected empty glass vial, however, no defects or complaints have been reported to date for these lots. Paclitaxel for Injection is a clear colorless to slightly yellow viscous solution and is indicated in the treatment of carcinoma of the ovary, breast or lung. Read more here.